Category Archives: Biotechnology

This story originally appeared on Zacks

Launched on 06/19/2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 12, placing it in bottom 25%.

Index Details

The fund is sponsored by First Trust Advisors. It has amassed assets over $1.71 billion, making it one of the larger ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. FBT seeks to match the performance of the NYSE Arca Biotechnology Index before fees and expenses.

The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Costs

Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.

Annual operating expenses for this ETF are 0.55%, making it on par with most peer products in the space.

It has a 12-month trailing dividend yield of 1.37%.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Biontech Se (adr) (BNTX) accounts for about 3.57% of total assets, followed by Moderna, Inc. (MRNA) and Charles River Laboratories International, Inc. (CRL).

The top 10 holdings account for about 34.33% of total assets under management.

Performance and Risk

The ETF has gained about 0% so far this year and is down about -2.27% in the last one year (as of 01/03/2022). In that past 52-week period, it has traded between $153.09 and $184.84.

The ETF has a beta of 0.90 and standard deviation of 25.10% for the trailing three-year period, making it a high risk choice in the space. With about 31 holdings, it has more concentrated exposure than peers.

Alternatives

First Trust NYSE Arca Biotechnology ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, FBT is a good option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $7.17 billion in assets, iShares Biotechnology ETF has $10.07 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want key ETF info delivered straight to your inbox?

Zacks free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportFirst Trust NYSE Arca Biotechnology ETF (FBT): ETF Research ReportsCharles River Laboratories International, Inc. (CRL): Free Stock Analysis ReportModerna, Inc. (MRNA): Free Stock Analysis ReportiShares Biotechnology ETF (IBB): ETF Research ReportsSPDR S&P Biotech ETF (XBI): ETF Research ReportsBioNTech SE Sponsored ADR (BNTX): Free Stock Analysis ReportTo read this article on Zacks.com click here.

Here is the original post:
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Entrepreneur

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on demand beginning at 7:00 a.m. EST on January 10, 2022.

The presentation will be available for replay for 30 days on the Companys website at http://www.pumabiotechnology.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005861/en/

See the rest here:
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference - marketscreener.com

Latest Market intelligence report released by Adroit Market Research with title Global White Biotechnology Enzymes Market Size, Status and Forecast 2021-2028 is designed covering micro level of analysis by manufacturers and key business segments. The Global White Biotechnology Enzymes Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing.

Whats keeping Companies Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by Adroit Market Research

Get Free Sample Report + All Related Graphs & Charts @ https://www.adroitmarketresearch.com/contacts/request-sample/1412?utm_source=pr

Market Overview of Global White Biotechnology Enzymes

If you are involved in the Global White Biotechnology Enzymes industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications [Social Media Marketing, E-mail Marketing, SEO Marketing, PPC Marketing & Other], Product Types [, On Premises & Cloud Based] and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market along with impact of economic slowdown.

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019Base year 2020Forecast period** 2021 to 2028 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

To know more about the table of contents, you can click @ https://www.adroitmarketresearch.com/industry-reports/white-biotechnology-enzymes-market?utm_source=pr

White Biotechnology Enzymes Market Segmentation:

The global White Biotechnology Enzymes market study provides users with an insightful data on several factors such as social, environmental, political, etc. that can influence White Biotechnology Enzymes market growth. The detailed study factors such as social, environmental, political, etc. that can influence White Biotechnology Enzymes market growth. Furthermore, the White Biotechnology Enzymes market study also offers detailed note on the strategies associated with the growth of the industry.

The Study Explore the Product Types of White Biotechnology Enzymes Market:

by Type (Carbohydrase, Proteases, Lipases& Others)

Key Applications/end-users of Global White Biotechnology Enzymes Market:

by Industry (Industrial Enzymes and Specialty Enzymes)

Market segment by Region/Country including:

Make an enquiry of this report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1412?utm_source=pr

The report also provides deep insights on the opportunities for investments in the White Biotechnology Enzymes sectors helping the stakeholders looking for it. Also the research states the comprehensive study on the sales, production, costs and profit margins in the industry. The information included in the report regarding all these crucial matters of the White Biotechnology Enzymes market is supported with accurate and reliable numerical data.

Queries we have tried to answered in Global White Biotechnology Enzymes Market Study:

1. Who are the Leading key players and what are their Key Business strategies in the Global White Biotechnology Enzymes?2. What are the key consequences of the five forces analysis of the White Biotechnology Enzymes?3. What are different opportunities and threats faced by the dealers in the Global White Biotechnology Enzymes?4. What are the strengths and weaknesses and business strategies of the key vendors?

Some Extracts from Table of Contents:

3.1. Market Segmentation3.2. Industry landscape, 2015 20263.3. Industry ecosystem analysis3.3.1. Raw material suppliers3.3.2. Manufacturers3.3.3. Distribution channel analysis3.3.4. Vendor matrix3.4. Technology landscape3.5. Raw material analysis by Type[, On Premises & Cloud Based]3.5.5. Raw material supply, by region3.5.5.1. North America3.5.5.2. Europe3.5.5.3. Asia Pacific3.5.5.4. LATAM3.5.5.5. MEA3.6. Regulatory landscape3.7. Industry best practices & key buying criteria3.8. Pricing analysis3.9.1. Regional pricing3.9.1.1. North America3.9.1.2. Europe3.9.1.3. Asia Pacific3.9.1.4. Latin America3.9.1.5. MEA3.10 Cost structure analysis3.10.1. Impact on pricing3.11. Industry impact forces3.11.1. Growth drivers3.11.2. Industry pitfalls & challenges3.12. Innovation & sustainability3.12.1. Future trends and Impact3.12.1.1. Production trends3.12.1.2. Demand trends3.13. Growth potential analysis3.14. Porters analysis3.14.1. Supplier power3.14.2. Buyer power3.14.3. Threat of new entrants3.14.4. Threat of substitutes3.14.5. Industry rivalry3.15. Competitive landscape3.15.1. Company market share analysis, 20193.15.2. Strategy landscape3.16. PESTEL analysis3.17.

Our Report Offers:1. Detailed inquiry of market estimations for all the segments2. Thorough market analysis from the viewpoint of the leading market players3. Strategic approaches for new entrants4. Market forecasts on regional basis for the next decade5. Competitive analysis of the current market trends6. Company profiling along with an explicit strategy and economic developments

ABOUT US:Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

CONTACT US:Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 210-667-2421/ +91 9665341414

Excerpt from:
How Technology is Disrupting the White Biotechnology Enzymes Market by BASF SE , Amano Enzyme Inc, Novus International, Inc Industrial IT -...

Global Bioreactors market report contains a detailed analysis of the current state and future scope along with the sales patterns, market size, share, price structure, and market progressions. The study discusses the underlying trends and impact of various factors that drive the market, along with their influence on the evolution of the Bioreactors market. This report briefly deals with the product life cycle, comparing it to the relevant products from across industries and then evaluates the snapshot given by Porters five forces analysis for identifying new opportunities in this industry. A thorough evaluation of the restrain included in this report portrays contrast to drivers which helps make strategic planning easier.

Get a Sample PDF of the report at https://www.datalabforecast.com/request-sample/326082-bioreactors-market

North America is expected to hold dominant position in the global Bioreactors market, owing to increasing collaboration activities by key players over the forecast period.

The report also comprises the study of current issues with end users and opportunities for the Bioreactors market. It also contains value chain analysis along with key market participants. To provide users of this report with a comprehensive view of the Bioreactors market, we have included a detailed competitive analysis of market key players. Furthermore, the report also comprehends business opportunities and scope for expansion.

List of Top Key Players in Bioreactors Market Report are:

Applikon Biotechnology, Pall Corporation, GE Healthcare, Sartorius AG, Eppendorf, Thermo Fisher Scientific, Cellexus, Celltainer Biotech BV, Finesse Solutions, Merck Millipore, PBS Biotech, Cellution Biotech, CerCell ApS, Electrolab Biotech, Infors AG, Pierre Guerin, Techniserv, Bioengineering AG, Broadley-Jamesn.

The qualitative data gathered by extensive primary and secondary research presented in the report aims to provide crucial information regarding market dynamics, market trends, key developments and innovations, and product developments in the market. It also provides data about vendors, including their profile details which include product specifications, applications and industry performance, annual sales, revenue, relevant mergers, financial timelines, investments, growth strategies and future developments.

The biggest highlight of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19 which will help market players in this field to evaluate their business approaches. At the same time, this report analyzed the market of leading 20 countries and introduce the market potential of these countries.

We are currently offering Quarter-end Discount to all our high potential clients and would really like you to avail the benefits and leverage your analysis based on our report.

To Know How COVID-19 Pandemic Will Impact Bioreactors Market/Industry- Request a sample copy of the report- https://www.datalabforecast.com/request-sample/326082-bioreactors-market

Market Analysis and Insights: Global Bioreactors Market

In 2020, the global Bioreactors market size was USD million and it is expected to reach USD million by the end of 2027, with a high CAGR between 2021 and 2027

Global Bioreactors Scope and Market Size

The global Bioreactors market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Bioreactors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.

Enquire before purchasing this report https://www.datalabforecast.com/request-enquiry/326082-bioreactors-market

Bioreactors Market

Global Bioreactors Market Segment Analysis:

This report focuses on the Bioreactors market by volume and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Bioreactors market size by analyzing historical data. Additionally, type-wise and application-wise consumption tables and figures of the Bioreactors market are also given. It also distinguishes the market based on geographical regions like North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.

By the product type, the market is primarily split into

Single-use Bioreactors, Multiple-use Bioreactors.

By the end-users/application, this report covers the following segments

Food Industry, Pharmaceutical, Sewage Treatment, Biochemical Engineering, Others.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1 917-725-5253 to share your research requirements.

Contact:Henry KData Lab Forecast86 Van Wagenen Avenue, Jersey,New Jersey 07306, United States

Phone: +1 917-725-5253Email: [emailprotected]

Website: https://www.datalabforecast.com/Explore News Releases: https://newsbiz.datalabforecast.com/

Follow Us on: LinkedIN | Twitter |

More Trending Reports by Data Lab Forecast:

Read the original:
Bioreactors Market Will Hit Big Revenues In Future | Applikon Biotechnology, Pall Corporation, GE Healthcare and more Industrial IT - Industrial IT

The major food staples are essential to human survival. Chocolate and coffee are not essential, but try to imagine a world without them. One of the numerous concerns with climate change is that many species will lose their habitats. Scientists are projecting that, in the coming decades, this could lead to the extinction of many crops, including cacao and coffee plants.

The cacao tree is native to the Amazon Basin in South America. Over 1,500 years ago, the Mayas and other cultures in South and Central America cultivated the plant, and todayover 90 percent of the worlds cocoa is grown on small family farms. The cacao plants range is a narrow strip of rainforest roughly 20 degrees north and south of the equator, where the temperature, rain, and humidity are relatively constant throughout the year.

Like tropical fruits native to Hawaii, the cocoa industry has been ravaged by fungal infections. In Costa Rica, it never recovered from a fungal outbreak in the 1980s. The most recent outbreak occurred in Jamaica in 2016. Attempts by scientists to breed and create new hybrid varieties have failed. Today, most varieties of the cocoa plant are derived from genetically engineered plants or clones selected in the 1940s, which means they are susceptible to the same fungal diseases from the past.

Today,two West AfricancountriesCte dIvoire and Ghanaproduce over half of the worlds chocolate. By 2050, rising temperatures could push the current growing regions more than 1,000 feet uphill into mountainous terrain, an area nowmostly preserved for wildlife, according to the National Oceanic and Atmospheric Administration. Europe and the United States currently have large markets for cacao, while the demand in India and China is steadily growing. The reduced humidity caused by rising temperatures will make cacao trees extremely vulnerable and threaten the chocolate industry.

In contrast, the coffee plant has a variety of species. Temperature and rainfall conditions are the main drivers of crop yield. Scientists are projecting longer and more extreme periods of rain and drought, and along with rising temperatures, this could reduce the area suitable for growing coffee byup to 50 percentby 2050. Anextensive study foundthat of the worlds 124 wild coffee species, 75 (roughly 60 percent) are at risk of extinction due to climate change.

If scientists can identify which genes of the cacao and coffee plants to modify to adapt to new environmental conditions, they can help them survive. Researchers at the University of California, Berkeley, and Mars, a manufacturer of food products, are collaborating to conserve the cacao plant. In 2008, Marslaunched the Cacao Genome Projectto identify traits for climate change adaptability and developing higher yield. The researchers are using the genome editing tool CRISPR to edit the DNA of the cacao plant so that it can survive in warmer temperatures and drier conditions, and grow in different climates.

Genome editing allows breeders to introduce new traits more precisely and rapidly, potentially saving years or even decades in bringing needed new varieties to farmers. The US Department of Agriculture (USDA)does not plan to regulategene-edited plants or crops if they have traits similar to plants developed through traditional breeding techniques. However, the Food and Drug Administration (FDA)has the final sayover the safety of food for human consumption.

Other alternatives to coffee-as-we-know-it includeartificial coffeeproduced in a lab, which would require government approval, and moving millions of coffee farmers to new habitats. These options might make genome editing more appealing to activists.

The conventional wisdom is that farming is an organic practice and that tinkering with genes is risky and unethical. Advances in biological sciences have allowed scientists to provide a more balanced perspective on how farming practices and genetically modified organisms (GMOs) have impacted humans and our planet.

During the Agricultural Revolution, our ancestors transitioned from hunter-gathers to domesticating plants and animals. We now know that clearing the land increased global warming and standing water created breeding grounds for mosquitos which contributed to the spread of diseases such as malaria. Forests absorb greenhousegases and cattle emit methane during the food digestion process. Today, gases emitted by farm animalsaccount for 1418 percentof global greenhouse gas emissions. Domesticating farm animals has also led to numerous viral infections and poxes in humans which have produced epidemics.

In 1970, President Richard Nixon launched the War on Cancer to better understand the factors related to the development of tumors. Some scientists researched mutations caused by chemicals, the sun, and bombs, while others focused on viruses and bacteria that invade human cells. They discovered the molecular mechanisms used by viruses and bacteria which enabled the field of genetic engineering. They can use the same mechanisms to insert DNA with desired traits.

Genetic engineering has enabled scientists to develop life-saving drugs, produce food sources that can resist fungal and viral infections and live in harsh conditions, and prevent plant species from becoming extinct. In addition, it has stimulated the economy through job creation and hundreds of billions of dollars.

Traditional economics assumes that when humans make decisions they rationally weigh the costs and benefits and calculate the best choices for themselves. Behavioral economics, on the other hand,provides valuable insightsinto why some individuals do not behave in their own best interests. Some people make irrational choices based on errors and biases, while others utilize slow thinking, acquire new information, and are rational updaters.

Biotechnology companies have offered genetically engineered products in American markets since the 1980s. Given that both genetic engineering and recombinant DNA products have not caused any health and environmental problems during that time period, it is unclear why they are not more universally accepted.

In the absence of state and federal laws, scientists took it upon themselves to develop a plan on how to proceed safely with genetic engineering or recombinant DNA technology inside the lab. This led to the 1975 Asilomar Conference organized by the National Academy of Sciences held for four days in Pacific Grove, California. One hundred and forty biologists and physicians, four lawyers, and 12 journalists assembled to discuss the potential risks involved with recombinant DNA technology and to discuss and establish the conditions under which research should proceed.

While researching the mechanisms of cancer, scientists discovered that viruses can alter human cells in culture and transform cell lines into a cancerous state. At the time, they were concerned with the potential dangers of viruses if they spread in labs, while activists were worried they might harm the environment and infect humans outside the labs if they were misused. The scientists agreed to a voluntary moratorium on certain types of recombinant DNA experiments and containment on others until the risks were better understood.

Only months after the Asilomar Conference in 1975, as Chairman of the Subcommittee on Health, Senator Edward Kennedy chaired a hearing on genetic engineering and recombinant DNA. Kennedy was initially inclined to have an extended moratorium on research and allow more time for viewpoints from the concerned public and activists. The City Council of Cambridge, Massachusetts, did declare a moratorium on research, an act that was followed by similar bans in a number of other cities.

After further research, however, scientists learned that if they applied a knockouta technique used to make a harmful gene inoperativeit would make the virus harmless. In his 2001 book, A Passion for DNA, James Watson recalls that Kennedy then did an about-face and said, Following a period without the determination of any real risks; public hysteria cannot be maintained indefinitely in the absence of a credible villain of recombinant DNA technology. The Asilomar Conference has provided a successful framework for assessing the risks of emerging technologies.

In order to provide oversight in the lab, it is necessary to understand the technical aspects of genetic engineering, and to distinguish between real and perceived risks. Without the technical understanding there is a tendency to conflate oversight of the process and the product. Genetic engineering is a lab procedure used to recombine DNA (a process). Scientists can recombine DNA from two different species in order to produce an animal or plant with a desired trait (a product). Now that scientists have made the lab procedure safe, it is the responsibility of the appropriate federal government agenciesincluding the FDA, USDA, and Environmental Protection Agency (EPA)to test and approve the products.

Regulating the risks and safety of automobiles provides an interesting analogy which makes these concepts easier to understand than learning the technical aspects of molecular biology. In the United States, when the production of a Ford vehicle makes it to the Ford factory, the Occupational Safety and Health Administration (OSHA) provides oversight for the safety of the factory workers. As the car moves from a dealership to the highways, the Department of Transportation (DOT) and other government agencies mandate safety precautions such as seat belts, speed limits, laws on texting while driving, air bags, and so on to make driving safer and ultimately lower the fatality rate on American highways.

Human procreation is also a process that recombines DNA. Randomly and through natural selection, it recombines genes from the male and female genomes. In this case, the outcome is more unpredictable. But when DNA is recombined using genetic engineering, genes are selected for their functions.

Scientists later suggested that the National Institutes of Health (NIH) should form a Recombinant DNA Advisory Committee to establish safety guidelines, standards for conducting experiments, and oversight for NIH-funded projects. In 1976, a committee composed of experts in the field set safety guidelines matching the type of containment necessary for different types of experiments. Similar to the containment facilities for research on nuclear weapons during World War II, the levels of risk were categorized as minimal, low, moderate, and high, and required that scientists followed the appropriate safety standards and procedures at each level.

Given the uncertainty of outcomes with human procreation and the guidelines of the committee, one participant at the Asilomar Conference realized that they had just made human procreation amoderate risk experiment.

Historically, scientists have not fully understood the risks of most of the important technological innovations at the time of their invention.Today, the use of GM crops in the United States, South America, and Asia is a mainstream practice. The United States uses the proactionary principle, according to which risk assessment is based on science and self-regulation utilizing experts in the field.

The proactionary approach utilizes proportionality with an equal emphasis on risks and benefits. Restrictive measures are employed only if the potential impact of an activity is both significantly probable and severe, and the restrictions areproportionate to the extent of the risk. With the Asilomar model, manufacturers are held liable for the safety of their products, and regulators must demonstrate that they are not squandering resources and delaying social benefits to address minimal gains in safety.

Some European countries have utilized the precautionary principle for GMOs. With the precautionary approach, the burden of proof is on a manufacturer to prove the health and environmental impacts related to a new product is safe before it is approved. Using the precautionary approach, farmers have suffered financial losses and the benefits of products which can alleviate food shortages and nutritional deficiencies to citizens were delayed or denied.

In 1982,Genentechdeveloped the worlds first genetically engineered drug for patients suffering from Type I diabetessynthetic insulin. Prior to synthetic insulin, diabetes patients used insulin derived from human cadavers and animal insulin derived from pigs, sheep, and cows. Using the precautionary approach would have significantly delayed the medical benefits to many diabetics.

Societies do not accept the risks of technologies equally. Americas social contract with automobiles is very different than GMOs. According to the National Highway Traffic Safety Administration, over the last 20 years, Americans have accepted roughly40,000 annual traffic fatalitiesin return for a convenience that is engrained as part of our lifestyle. This figure fluctuates with regulations including speed limits and safety features in the automobiles, and technologies such as smart phones with texting which cause distractions.

To ensure citizens safely receive the social benefits of biotechnology, oversight would ideally take place through a rigorous clinical trials process similar to the pharmaceutical industry. However, the drug trials are time-consuming and cost-prohibitive for the development of most industrial products, and most biotechnology companies would likely not pursue development. Even with the time and costs dedicated to pharmaceutical clinical trials, a1998 study revealedthat roughly 106,000 people die each year in American hospitals as the result of the adverse health effects or side effects from prescribed medication.

In the past, failed regulatory oversight of the chemical industry left legacy issues and is a legitimate concern. With irrational fears, perhaps due to the inability to differentiate between science fiction and reality, activists are holding the biotechnology industry to a higher standard than other technologies.

Thousands of years ago, humans relied on wind and water wheels for power which were neither reliable nor scalable. Prior to the Second Industrial Revolution (18701914) human labor and farm animals were the major sources of power. Then electricity and internal combustion engines powered by fossil fuels lifted billions of people out of poverty and contributed to the growth of the middle class, reducing the number of hours they had to work and the amount of disposable income spent on subsistence.

In the 1950s, automobiles led to the rise of the suburban lifestyle in the US with gas-guzzling station wagons, modern kitchens, and numerous household appliances. Unfortunately, the Second Industrial Revolution is also remembered for contributing to climate change, and the start of the Anthropocene epoch is characterized by the influence of human activities on land-use changes, deforestation, and burning fossil fuels which accelerated species extinction and global warming.

Scholars have pointed out that, based on these human activities, the Anthropocene would have begun before the Second Industrial Revolution. Paul Crutzen argues that if it began with the production of carbon dioxide and methane at rates sufficient to alter the composition of the atmosphere this would coincide with James Watts design of the steam engine in 1784. William Ruddiman suggests that it began even earlier, and that the Agricultural Revolution that began around 8,000 years ago is a more accurate starting point.

Professional futurists look into the past to better understand probable scenarios for the future. Looking towards the future, societies should focus on making climate change manageable using this knowledge and learning how to best adapt to its inevitable effects. Much of the climate change debate is focused on causality. Deforestation, farming, cow flatulence, and using appliances and internal combustion engines are all contributors. Regardless of the politics of climate change, the effects are the same. Hopefully, planners, business executives, and public policy officials will have a game plan for adapting to the Anthropocene.

Given that climate change is occurring, regardless of the causenatural, man-made, or bothand that genome recombination and editing have enabled scientists to deliver a variety of foods and drugs safely, there is at least one option to prevent numerous species from becoming extinct. Thanks to advances in science and rational thinking, we gourmet chocolate and coffee lovers can continue to feed our addictions. This will confront GM opponents with a trilemmalabeled GM coffee, the artificial variety, or do without.

Randall Mayes is a technology analyst, author, futurist, and instructor of emerging technologies in Duke Universitys OLLI program.

A version of this article was originally posted at Quillette and is reposted here with permission. Quillette can be found on Twitter @Quillette

Read more from the original source:
What's the key, mostly missing, innovation that can help us adapt to severe climate change? Agricultural biotechnology - Genetic Literacy Project

The market study on the global Biotechnology Reagent market will encompass the entire ecosystem of the industry, covering major regions namely North America, Europe, Asia Pacific, South America, Middle East & Africa, and the major countries falling under those regions.

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Global Biotechnology Reagent market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

The market study covers the Biotechnology Reagent market size across different segments. It aims at estimating the market size and the growth potential across different segments, including application, type, organization size, vertical, and region. The study further includes an in-depth competitive analysis of the leading market players, along with their company profiles, key observations related to product and business offerings, recent developments, and market strategies.

Download Sample PDF at https://www.insidemarketreports.com/sample-request/14/952887/Biotechnology-Reagent

Leading players of the Biotechnology Reagent Market covered in this report are Agilent Technologies, BD, Merck, Bio-Rad Laboratories, Thermo Fisher Scientific,

The report is segmented based on product type are Chromatography, Ivd, Pcr Cell Culture, Flow Cytometry, Mass Spectrometry, Electrophoresis, etc.

Major applications of the Biotechnology Reagent market is segmented as Gene Expression, Drug Testing, Dna And Rna Analysis, Protein Purification, etc.

Biotechnology Reagent Market Regional Segment Analysis includes Regional Consumption Volume, Revenue and Growth Rate 2016-2027. Countries covered in this report are United States, Canada, Mexico, Brazil, Argentina, Columbia, Chile, Peru, Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland, GCC, North Africa, South Africa, China, Southeast Asia, India, Japan, Korea, Western Asia.

An Overview of the Impact of COVID-19 on this Market:

Effect of COVID-19: Biotechnology Reagent Market report investigate the effect of Coronavirus (COVID-19) on the Biotechnology Reagent industry. Since December 2019, the COVID-19 infection spread to practically 180+ nations around the world with the World Health Organization pronouncing it a general wellbeing crisis. The worldwide effects of the Covid infection 2020 (COVID-19) are now beginning to be felt, and will essentially influence the Biotechnology Reagent market in 2020 and 2021.

Notwithstanding, this also will pass. Rising help from governments and a few organizations can help in the battle against this exceptionally infectious illness. There are a few ventures that are battling and some are flourishing. Generally speaking, pretty much every area is expected to be affected by the pandemic.

We are taking persistent endeavors to assist your business with maintaining and develop during COVID-19 pandemics. In view of our experience and aptitude, we will offer you an effective examination of Covid flare-up across enterprises to assist you with setting up whats to come.

Cautious assessment of the components molding the Biotechnology Reagent market size, share, and the development direction of the market;

Get the insights to understand the Impact of COVID19 and drive the business strategies: https://www.insidemarketreports.com/covid-19/14/952887/Biotechnology-Reagent

This study will address some of the most critical questions which are listed below:

Major Points from the Table of Contents

1 Biotechnology Reagent Market Overview

2 Global Biotechnology Reagent Market Competition by Manufacturers

3 Global Biotechnology Reagent Capacity, Production, Revenue (Value) by Region)

4 Global Biotechnology Reagent Supply (Production), Consumption, Export, Import by Region

5 Global Biotechnology Reagent Production, Revenue (Value), Price Trend by Type

6 Global Biotechnology Reagent Market Analysis by Application

7 Global Biotechnology Reagent Manufacturers Profiles/Analysis

8 Biotechnology Reagent Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Biotechnology Reagent Market Forecast

13 Research Findings and Conclusion

14 Appendix

Why Inside Market Reports:

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

Hair Market Size, Growth and Global Forecast to 2027

Emergency Ambulance Market Size, Growth and Global Forecast to 2027

Breath Analyzers Market Size, Growth and Global Forecast to 2027

Extra Virgin Olive Oil Market Business Status, Industrial Outlook 2020 and 15 Top Players (Lamasia, Sovena Group, Gallo, Grup Pons, More)

Read the original here:
Biotechnology Reagent Market Technological Growth 2021-2027 with Types, Applications and Top Companies Industrial IT - Industrial IT

TOKYO, Jan. 4,2022 /PRNewswire/ -- PRISM BioLab, aJapan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group.

Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon identification of hit compounds, Roche and Genentech may elect tofurther develop and commercialize the compounds.

PRISM BioLab is eligible to receive an upfront payment, success-based milestone payments and royalties on future net sales. Specific financial terms are not disclosed.

About PRISM BioLab

PRISM BioLab Co., Ltd., is a biotechnology company with a proprietary small molecule drug discovery platform "PepMetics Technology". The PepMetics molecules are designed to mimic -helix or -turn peptides using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using this small molecule technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed. Further, PRISM BioLab is working on new drug targets in collaboration with Global and Japanese pharmaceutical companies.

Contact: PRISM BioLab Co., Ltd. [emailprotected] 26-1, Muraoka-Higashi 2-chome. Fujisawa, Kanagawa 251-8555 http://www.prismbiolab.com

SOURCE PRISM BioLab Co., Ltd.

Continued here:
PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech - PRNewswire

Global Marine Biotechnology Market 2021-2025 The analyst has been monitoring the marine biotechnology market and it is poised to grow by $ 3. 31 bn during 2021-2025, progressing at a CAGR of almost 9% during the forecast period.

New York, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Marine Biotechnology Market 2021-2025" - https://www.reportlinker.com/p05273066/?utm_source=GNW Our report on the marine biotechnology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in demand for biofuel and increased demand for secondary metabolites from marine microorganisms. In addition, increase in demand for biofuel is anticipated to boost the growth of the market as well.The marine biotechnology market analysis includes the application segment and geographic landscape.

The marine biotechnology market is segmented as below:By Application Healthcare products Energy and environment management products Food and cosmetics products

By Geographical Landscape North America Europe Asia ROW

This study identifies the rising demand for natural compounds in cosmetic industry as one of the prime reasons driving the marine biotechnology market growth during the next few years.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on marine biotechnology market covers the following areas: Marine biotechnology market sizing Marine biotechnology market forecast Marine biotechnology market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading marine biotechnology market vendors that include AKER BIOMARINE AS, BASF SE, CP Kelco US Inc., Cyanotech Corp., LAIR LIQUIDE SA, Lonza Group Ltd., Marinomed Biotech AG, PharmaMar SA, and Sea Run Holdings Inc. Also, the marine biotechnology market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p05273066/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Link:
The Global Marine Biotechnology Market is expected to grow by $ 3.31 bn during 2021-2025, progressing at a CAGR of almost 9% during the forecast...

SEATTLE--(BUSINESS WIRE)--Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and acquisition of Orthogonal Biologics, a deep mutational scanning protein engineering spin-out from the University of Illinois at Urbana Champaign. The financing includes investments from OrbiMed Advisors, Trinity Ventures, Agent Capital, Yard Ventures, Washington Research Foundation (WRF), iSelect Fund, a leading Asian private equity firm, W Fund, family offices, and individual investors. Selecta Bioscience joined the financing as a strategic investor.

We are thrilled to bring together a range of experienced biotech investors from across the globe to support our move into independent drug discovery, said Cyrus CEO Lucas Nivon. Over the last four years we have worked with dozens of companies such as Janssen and other global pharmaceuticals to advance their biologics, honing and validating our algorithms in the process.

Erik Procko, formerly CEO at Orthogonal Biologics, added that, By merging our company with Cyrus we can create a unified biologics discovery platform, building on Cyruss years of software development and business relationships to create value across a range of indications where progress was previously impossible. In some cases progress has been stalled for decades, or an effective drug has never been discovered. We can change the progress of disease for many patients and, over time, in dozens of indications where our technology offers new opportunity and hope.

Cyrus is focusing the combined software-and-screening platform on the re-design of natural proteins to produce superior biologics of unique efficacy and safety, meeting unmet medical needs for a range of indications. The firm has initiated a variety of in-house and partnered programs during the past 12 months, and the Orthogonal acquisition now adds a broad-spectrum protein-based COVID-19 therapeutic and another biologic to the pipeline. Programs in autoimmunity are being carried out in partnership with Selecta Biosciences, announced earlier this year. Cyrus also previously announced its collaboration with The Broad Institute in next-generation CRISPR engineering for reduced immunogenicity.

Cyruss software platform is based on years of work in computational biophysics and the first software algorithms to computationally design entirely new proteins with the Rosetta software package developed by David Bakers lab at UW. On top of Rosetta, Cyrus incorporates proprietary AI algorithms and a range of bioinformatics and cheminformatics tools, cloud infrastructure, and rigorous benchmarking with internal and partnered data. This unified set of biologics discovery tools has helped advance a number of Cyruss partners molecules to pre-clinical development and IND. Orthogonal Biologics and Dr. Prockos laboratory at UIUC have developed a uniquely powerful deep mutational scanning system, with capabilities across a range of protein and cell types, to produce accurate and highly human-relevant data for protein engineering. These capabilities have been used to identify and patent an exhaustive set of ACE2 receptor variants which serve as SARS-CoV-2 decoys and have significant therapeutic value. A subset now validated in animal studies shows unique resistance to novel emerging COVID variants when compared with antibodies and other therapeutics. This combined set of capabilities allows Cyrus to identify novel, effective and safe biologics more rapidly than with existing methods commonly used in BioPharma.

Geeta Vemuri, founder and managing partner at Agent Capital added, Rosetta has been well-known for years in academia, and Cyrus has proven the power of its Rosetta-based platform as a software and services company. We are very excited to now apply those software and laboratory tools directly for Cyruss partners and in house drug discovery.

About Cyrus Biotechnology

Cyrus Biotechnology is a pre-clinical-stage biotech company combining computational and experimental protein design and screening to create novel biologics for serious unmet medical needs. Using this approach, Cyrus is developing an early pipeline of innovative programs in multiple indications. The Cyrus platform improves both the efficacy (binding affinity, aggregation propensity, solubility, and stability) and safety (binding specificity and immunogenicity) of natural proteins. Cyrus is also partnering with leading biotech and pharma companies and research institutes to bring collaborative programs forward from discovery to the clinic. Cyrus is based on core software from the lab of David Baker at the University of Washington. Cyrus has worked with over 90 industry partners. The company is based in Seattle, WA and financed by leading US and Asian biotech and tech investors including Orbimed, Trinity Ventures, Springrock, Agent Capital, iSelect, Yard Ventures, WRF, and Alexandria. For more information about Cyrus please visit https://cyrusbio.com/.

NOTICE: The information contained in this document is dated as of November 30, 2021. Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date. This document contains forwardlooking statements reflecting the Companys current expectations that necessarily involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

View original post here:
Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug...

SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant.

To access the call via telephone, please dial (833) 727-9519 (North America) or (830) 213-7696 (International), conference ID: 9894016.

A live webcast of the call can be accessed under Events & Presentations in the Investors section of the Vir website atwww.vir.bioand will be archived there for 30 days.

About Vir BiotechnologyVir Biotechnologyis a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visitwww.vir.bio.

See the original post here:
Vir Biotechnology to Host a Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant - GlobeNewswire